Introduction
============

As breast cancer is the most commonly diagnosed disease in females in the USA[@b1-ott-9-6407] and the People's Republic of China,[@b2-ott-9-6407] it requires more attention. Increased knowledge of breast cancer revealed that it is a much more heterogeneous disease than was previously known. Classic subclassification of this cancer with estrogen receptor (ER), progesterone receptor, and HER2 may be no longer sufficient.[@b3-ott-9-6407] More personalized treatments that are more targeted may lead to superior efficacy and less toxicity.[@b4-ott-9-6407] Thus, new biomarkers and therapy targets are required.

G protein-coupled estrogen receptor 1 (GPER1), or G protein-coupled receptor 30, is a homologue of seven-transmembrane domain receptor, G protein-coupled receptor (GPCR), which was first found in the 1990s.[@b5-ott-9-6407] Followed by estrogen receptor-α (ERα) and ERβ, GPER1 was recognized as a new estrogen target. Later, it was found that GPER1 can activate epidermal growth factor receptor (EGFR) through matrix metalloproteinases-mediated release of heparin-binding EGF (HB-EGF).[@b6-ott-9-6407]--[@b8-ott-9-6407] Then, EGFR substrates mitogen-activated protein kinases (MAPKs)[@b8-ott-9-6407] and PI3-kinase (PI3K)[@b9-ott-9-6407] may be activated, followed by the activation of c-fos[@b10-ott-9-6407] and c-jun.[@b11-ott-9-6407] In addition, GPER1 can also lead to rapid activation of protein kinase A (PKA) pathway[@b12-ott-9-6407] and of PKA's downstream cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB).[@b13-ott-9-6407]

It was found universally that GPER1 was expressed in various cancers, including lung, prostate endometrial, ovarian, thyroid, and breast cancers,[@b14-ott-9-6407]--[@b18-ott-9-6407] and it can be activated by diverse ligands. Except for estrogen, ERα antagonists, tamoxifen and fulvestrant, were also found to be used as agonists of GPER1.[@b9-ott-9-6407],[@b19-ott-9-6407] Other ligands include vitamins,[@b20-ott-9-6407] aldosterone,[@b21-ott-9-6407] and some environmental contaminants.[@b22-ott-9-6407]

Although functionally and universally involved in cancers, the role of GPER1 in prognosis remains controversial. It was reported that GPER1 plays a role in stimulating cancer cell proliferation,[@b23-ott-9-6407]--[@b26-ott-9-6407] and it was also reported that GPER1 functions as a tumor suppressor.[@b27-ott-9-6407]--[@b30-ott-9-6407] Therefore, this research, aimed to find out whether GPER1 is a tumor suppressor or a stimulator by using 167 breast cancer samples and online data sets.

Materials and methods
=====================

Patients and samples
--------------------

All the 167 patients with breast cancer were diagnosed and treated with surgery from January 2009 to December 2009 in Fudan University-affiliated Shanghai Cancer Center (FDUSCC). Breast cancer samples were stored at −80°C immediately after resections. Histopathological analyses were conducted according to the guidelines of the American Society of Clinical Oncology/College of American Pathologists by the Department of Pathology in FDUSCC. All these 167 cases were followed up for \>20 months ([Table S1](https://www.dovepress.com/get_supplementary_file.php?f=111846.pdf)).

RNA isolation and retro-polymerase chain reaction (PCR)
-------------------------------------------------------

RNA was isolated with TRIzol^®^ reagent (Thermo Fisher Scientific, Waltham, MA, USA) by following the product protocol given by the manufacturer. Retro-PCR procedures were performed by using Bio-Rad Retro-PCR kit (Bio-Rad Laboratories Inc., Hercules, CA, USA) with product protocol.

Real-time PCR assays
--------------------

GPER1 and 18S RNA mRNA (inner reference) quantifications were performed by using Eppendorf realplex 4 with SYBR^®^ Green from Bio-Rad.

The primers are TGCACGAGCGGTACTACGA/GATGCCATCCAGATGAGGC and CAGCCACCCGAGATTGAGCA/TAGTAGCGACGGGCGGGTGT, respectively.

Online databases
----------------

[Table 1](#t1-ott-9-6407){ref-type="table"} lists all the available online data sets that could represent relationship between GPER1 expression and breast cancer prognosis and were selected under the guidelines available in [kmplot.com](http://kmplot.com)[@b31-ott-9-6407] and [www.prognoscan.org](http://www.prognoscan.org).[@b32-ott-9-6407]

Cell line and transfection
--------------------------

Triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-468 were purchased from Type Culture Collection of the Chinese Academy of Sciences, Shanghai, People's Republic of China. HER2 plasmid was pursued from GeneChem (Shanghai, People's Republic of China). Fugene^®^ 6 (Hoffman-La Roche Ltd., Basel, Switzerland) was used as a transfection reagent.

Western blotting analysis
-------------------------

Cell lysis was carried out by using sodium dodecyl sulfate gel with 8% acrylamide. Anti-HER2 was purchased from Bethyl (Montgomery, TX, USA); anti-GPER1, anti-p-CREB, and anti-vinculin (inner reference) were purchased from Abcam (Cambridge, MA, USA); and anti-mouse and anti-rabbit were purchased from Santa Cruz Biotechnology Inc. (Dallas, TX, USA).

Statistical analysis
--------------------

Kaplan--Meier (KM) plots and multivariable Cox regression analyses were conducted by using Statistical Package for the Social Sciences Version 16.0 (IBM Corporation, Armonk, NY, USA). Hazard ratios (HRs) of all the factors were achieved by using backward method in Cox regression analyses. Forest plots were performed with Stata Version 12.0 (StataCorp LP, College Station, TX, USA). Medium value was set as a cutoff in all cases. *P*\<0.05 was statistically significant. *P*-values of KM plot were calculated by using log rank test.

Ethical statement
-----------------

Permissions for scientific research usage of all breast cancer samples in this assay were obtained from patients before they underwent surgeries in FDUSCC. The ethics committee of FDUSCC did not require that ethical approval and informed patient consent be obtained for this study due its retrospective nature.

Results
=======

Clinical and pathological characteristics
-----------------------------------------

Among the 167 patients with breast cancer, 63.5% were aged \>50 years and 36.5% were \<50 years; 25.1% of patients were at T1 stage, and the remaining were at T2 or T3 stage; 45.5% of patients were lymph node positive, 40.1% were negative, and the remaining 14.4% were not informed; 75.4% of the samples were ER positive and 33.5% were HER2 positive; and 79.0% of patients underwent endocrine therapy, and 88.6% underwent chemotherapy.

ER and HER2 status might be related with GPER1 expression (*P*=0.043 and 0.090, respectively); thus, they might affect the role of GPER1 in prognosis under multivariate Cox regression analysis ([Table 2](#t2-ott-9-6407){ref-type="table"}).

Cox regression analysis of disease-free survival (DFS) and overall survival (OS)
--------------------------------------------------------------------------------

In univariate Cox regression analysis, none of the characteristics presented significant relationship with DFS. While it indicated that T stage, N stage, and HER2 status were correlated with patients' OS (HR =3.16, 95% confidence interval \[CI\] =1.05--9.54, *P*=0.041; HR =2.19, 95% CI =1.03--4.69, *P*=0.043; HR =3.17, 95% CI =1.04--9.69, *P*=0.043, respectively). In multivariate Cox regression analysis, it was found that N stage was related to DFS (HR =3.03, 95% CI =1.04--8.87, *P*=0.043), and none was significantly correlated with OS. In both univariate and multivariate analyses, GPER1 did not present any significant relationship with DFS or OS ([Tables 3](#t3-ott-9-6407){ref-type="table"} and [4](#t4-ott-9-6407){ref-type="table"}).

KM analysis of GPER1
--------------------

KM analysis found no significant relationship between GPER1 and breast cancer prognosis, but in HER2-overexpressed subgroup, it was found that lower expressed patients had better DFS than higher expressed patients (HR =4.47, 95% CI =0.93--21.56, log rank *P*=0.041). Conversely, in non-HER2-overexpressed or "HER2-negative" subgroup, it was found that GPER1-higher expressed patients had better distant metastasis-free survival (DMFS) and DFS (HR =0.23, 95% CI =0.05--1.07, log rank *P*=0.040); HR =0.27, 95% CI =0.08--0.99, log rank *P*=0.035, respectively; [Figure 1](#f1-ott-9-6407){ref-type="fig"}.

Cox regression analysis of DFS and OS in HER2-overexpressed subgroup
--------------------------------------------------------------------

In HER2-overexpressed subgroup, both T stage and N stage also played important roles in affecting breast cancer prognosis. In univariate Cox regression analysis, it was found that N stage were correlated with both worse DFS (HR =3.54, 95% CI =1.12--11.22, *P*=0.032) and worse OS (HR =3.17, 95% CI =1.00--10.06, *P*=0.050). In multivariate Cox regression analysis, T stage and N stage were correlated with worse DFS (HR =3.72, 95% CI =1.08--12.82, *P*=0.037; HR =8.15, 95% CI =1.05--63.47, *P*=0.045). Higher T stage was also implicated worse OS (HR =3.47, 95% CI =1.04--11.50, *P*=0.042). Besides, GPER1 was also found to be related to worse DFS (HR =7.57, 95% CI =1.03--55.58, *P*=0.047) in HER2-overexpressed subgroup ([Tables 5](#t5-ott-9-6407){ref-type="table"} and [6](#t6-ott-9-6407){ref-type="table"}).

Meta-analysis with online data sets
-----------------------------------

Considering that there might not be enough incidents in the present research, all the possible data sets that may reflect the role of GPER1in breast cancer prognosis were searched and collected from [kmplot.com](http://kmplot.com) and [www.prognoscan.org](http://www.prognoscan.org) ([Table 1](#t1-ott-9-6407){ref-type="table"}). By using all these available 26 online data sets and the present research, it was found that higher expressed GPER1 was slightly but significantly related to better recurrence-free survival (RFS; HR =0.91, 95% CI =0.85--0.99; [Figure 2](#f2-ott-9-6407){ref-type="fig"}). only 14 and eight data sets were available for DMFS and OS analysis, and neither of them was significantly correlated with GPER1 expression ([Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=111846.pdf)). Data sets that comprise HER2 subgroups were even fewer; only three data sets were available for RFS ([Figure S2](https://www.dovepress.com/get_supplementary_file.php?f=111846.pdf)) and one for DMFS and OS (data not shown).

Overexpression of HER2 in HER2-negative cell lines raised GPER1 level
---------------------------------------------------------------------

In order to investigate why the role of GPER1 differed in HER2-overexpressed patients from general population, HER2-overexpressed MDA-MB-231 and MDA-MB-468 cell lines were established. It was found that in both the cell lines, HER2 overexpression led to GPER1 increase in mRNA and protein level. As a substrate of GPER1 but not of HER2, CREB's higher phosphorylation also indicated that HER2 overexpression promoted GPER1 expression and function ([Figure 3](#f3-ott-9-6407){ref-type="fig"}).

Discussion
==========

It was not surprised that GPER1 was related with proliferation and migration of breast cancer,[@b23-ott-9-6407]--[@b26-ott-9-6407] as it was reported that it can be able to active MAPKs,[@b8-ott-9-6407] PI3Km[@b9-ott-9-6407] and PKA.[@b12-ott-9-6407] In contrast, there were more and more newly published data showing that GPER1 might play an anti-tumorigenesis role in breast cancer,[@b28-ott-9-6407]--[@b30-ott-9-6407] which is also coincided with what was found in the present meta-analysis ([Figure 2](#f2-ott-9-6407){ref-type="fig"}). In the present research, no evidence showed that GPER1 contributed to breast cancer progression in the general population ([Figures 1](#f1-ott-9-6407){ref-type="fig"} \[left\], [2](#f2-ott-9-6407){ref-type="fig"}, and [S1](https://www.dovepress.com/get_supplementary_file.php?f=111846.pdf)) but mildly correlated with better RFS ([Figure 2](#f2-ott-9-6407){ref-type="fig"}). It might be because that activation of GPER1 led to G2/M-phase cell cycle block with accumulation of G2-checkpoint proteins, cyclin B1 and Cdc2.[@b11-ott-9-6407],[@b27-ott-9-6407],[@b30-ott-9-6407] It might also raise p53 expression via intracellular calcium (Ca^2+^) mobilization, leading to p53-induced cell cycle arrest.[@b30-ott-9-6407] The prolongation of mitotic duration that disturbs regular cell cycle may then lead to cell apoptosis.[@b28-ott-9-6407] Therefore, GPER1 may be double-edged in tumor genesis, and the anti-tumor effect might take a slight advantage in general breast cancer patient population ([Figure 2](#f2-ott-9-6407){ref-type="fig"}).

But contrary to slight anti-tumor effect in general patient population, GPER1 seemed to be related with worse prognosis in HER2-overexpressed subgroup in the present research ([Figure 1](#f1-ott-9-6407){ref-type="fig"} \[middle\]; [Table 6](#t6-ott-9-6407){ref-type="table"}), and such tendency was also present in online data sets GSE17907 and E-MTAB-365, though without significance ([Figure S2](https://www.dovepress.com/get_supplementary_file.php?f=111846.pdf)). It may be because that GPER1 led to activation of matrix metalloproteases as mentioned previously, resulting in the release of EGFR ligand HB-EGF.[@b8-ott-9-6407],[@b18-ott-9-6407] As HER2 works as heterodimers combined with other HER family members such as EGFR, GPER1-induced HB-EGF abundance might trigger EGFR/HER2 substrate progresses.[@b33-ott-9-6407] On the other hand, evidences showed that activation of EGFR/ERK/c-fos raised GPER1 expression,[@b34-ott-9-6407],[@b35-ott-9-6407] and GPER1 was overexpressed in HER2-positive breast cancer patients.[@b36-ott-9-6407] Moreover, in the present study, it was shown that overexpressed HER2 led to higher GPER1 expression and function in HER2-negative cell lines ([Figure 3](#f3-ott-9-6407){ref-type="fig"}). Thus, in HER2-overexpressed patients, activation of HER2 pathway might enhance the "protumor edge" of GPER1 and cover its weak anti-tumor effect, as evidences showed that combined use of HER2 inhibitor trastuzumab and GPER1 agonist G1 provided better inhibitory effect in HER2-positive cell lines than the use of G1 alone.[@b37-ott-9-6407]

Conclusion
==========

In summary, by using 167 breast cancer samples and online data sets, the role of GPER1 was analyzed in breast cancer prognosis. In this meta-analysis, it was found that GPER1 may contribute to better prognosis in general breast cancer patients and especially in "HER2-negative" patients, but this is not the case in HER2-overexpressed patients, indicating that GPER1 plays a double-edged role in breast cancer prognosis.
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![Kaplan--Meier analysis of OS, RFS, DMFS, and DFS of patients according to GPER1 mRNA expression.\
**Notes:** No statistically significant difference was found in entire sample group (left column); in HER2-positive subgroup, GPER1-lower expressed patients have better DFS (middle column); in HER2-negative subgroup, GPER1-higher expressed patients have better DMFS and DFS (right column). Red lines stand for GPER1-higher expressed patients; black lines stand for GPER1-lower expressed patients. "HER2+" stands for HER2-overexpressed patients and "HER2−" stands for the remaining patients.\
**Abbreviations:** DFS, disease-free survival; DMFS, distant metastasis-free survival; GPER1, G protein-coupled estrogen receptor 1; OS, overall survival; RFS, recurrence-free survival; Cum, cumulative.](ott-9-6407Fig1){#f1-ott-9-6407}

![Forest plots of RFS analysis in online data sets combined with the present research.\
**Notes:** The overall HR was 0.91(0.85--0.99), *P*=0.021. Points represent average HR, and line segments stand for 95% confidence interval. Rhombus stands for overall average HR and 95% confidence interval.\
**Abbreviations:** ES, effect scale; HR, hazard ratio; RFS, recurrence-free survival.](ott-9-6407Fig2){#f2-ott-9-6407}

![Overexpression of HER2 in HER2-negative breast cell lines.\
**Notes:** Overexpression of HER2 in MDA-MB-231 (**A** and **C**) and MDA-MB-468 (**B** and **D**) raised GPER1 in protein level (**A** and **B**) and mRNA level (**C** and **D**), following with elevation of GPER1 substrate CREB phosphorylation (**A** and **B**).\
**Abbreviations:** CREB, cAMP response element-binding protein; GPER1, G protein-coupled estrogen receptor 1.](ott-9-6407Fig3){#f3-ott-9-6407}

###### 

Cited data sets

  Data set        Authors            Publication year   Citation   Data set         Authors               Publication year   Citation
  --------------- ------------------ ------------------ ---------- ---------------- --------------------- ------------------ ----------
  E-MTAB-365      Guedj et al        2012               38         GSE2034          Wang et al            2005               39
  E-TABM-158      Chin et al         2006               40         GSE20685         Kao et al             2011               41
  GSE11121        Schmidt et al      2008               42         GSE20711         Dedeurwaerder et al   2011               43
  GSE12093        Zhang et al        2009               44         GSE21653         Sabatier et al        2011               45
  GSE12276        Bos et al          2009               46         GSE2603          Minn et al            2005               47
  GSE1378         Ma et al           2004               48         GSE26971         Filipits et al        2011               49
  GSE1379         Ma et al           2004               48         GSE2990          Sotiriou et al        2006               50
  GSE1456-GPL96   Pawitan et al      2005               51         GSE31519         Rody et al            2011               52
  GSE16391        Desmedt et al      2009               53         GSE3494          Miller et al          2005               54
  GSE16446        Desmedt et al      2011               55         GSE5327          Minn et al            2007               56
  GSE17705        Symmans et al      2010               57         GSE6532-GPL570   Loi et al             2007               58
  GSE17907        Sircoulomb et al   2010               59         GSE7390          Desmedt et al         2007               60
  GSE19615        Li et al           2010               61         GSE9195          Loi et al             2008               62

###### 

Clinical and pathological characteristics

  Variables                                              Total patients   GPER1 higher   GPER1 lower   *P*-value
  ------------------------------------------------------ ---------------- -------------- ------------- -----------
  Total                                                  167              84             83            
  Age (years)                                                                                          
   \>50                                                  106 (63.5%)      56             50            
   ≤50                                                   61 (36.5%)       28             33            0.389
  T stage                                                                                              
   T1                                                    42 (25.1%)       20             22            
   T2 and T3                                             125 (74.9%)      64             61            0.688
  N stage                                                                                              
   Positive                                              76 (45.5%)       39             37            
   Negative                                              67 (40.1%)       28             39            0.255
   Unknown                                               24 (14.4%)       17             7             
  ER                                                                                                   
   Positive                                              126 (75.4%)      69             57            
   Negative                                              41 (24.6%)       15             26            0.043
  HER2                                                                                                 
   Positive                                              56 (33.5%)       23             33            
   Negative                                              111 (66.5%)      61             50            0.090
  TAM                                                                                                  
   Yes                                                   45 (26.9%)       25             20            
   No                                                    122 (73.1%)      59             63            0.409
  Other endo[a](#tfn1-ott-9-6407){ref-type="table-fn"}                                                 
   Yes                                                   93 (55.7%)       51             42            
   No                                                    74 (44.3%)       33             41            0.188
  Chemotherapy                                                                                         
   Yes                                                   148 (88.6%)      75             73            
   No                                                    19 (11.4%)       9              10            0.786

**Note:**

Other endo: other endocrine therapy except for TAM.

**Abbreviations:** GPER1, G protein-coupled estrogen receptor 1; TAM, tamoxifen treatment.

###### 

Univariate analysis of DFSand OS

  Factors                                                DFS HR   OS HR                                             
  ------------------------------------------------------ -------- ------- ------ ------- ------- ------ ----------- -------
  Age                                                    1.02     0.98    1.06   0.317   1.05    1.00   1.10        0.072
  T stage                                                1.90     0.81    4.47   0.139   3.16    1.05   9.54        0.041
  N stage                                                1.38     0.86    2.23   0.183   2.19    1.03   4.69        0.043
  ER                                                     1.10     0.41    2.99   0.846   0.52    0.17   1.59        0.252
  HER2                                                   1.38     0.59    3.22   0.463   3.17    1.04   9.69        0.043
  TAM                                                    1.27     0.52    3.11   0.605   0.81    0.22   2.96        0.754
  Other endo[a](#tfn3-ott-9-6407){ref-type="table-fn"}   1.40     0.59    3.32   0.453   0.93    0.31   2.76        0.894
  Chemotherapy                                           0.81     0.24    2.74   0.738   24.16   0.01   43,520.00   0.405
  GPER1                                                  0.55     0.23    1.30   0.174   0.84    0.28   2.51        0.76

**Note:**

Other endo: other endocrine therapy except for TAM.

**Abbreviations:** DFS, disease-free survival; ER, estrogen receptor; GPER1, G protein-coupled estrogen receptor 1; HR, hazard ratio; OS, overall survival; TAM, tamoxifen treatment.

###### 

Multivariate analysis of DFS and OS

  Factors                                                DFS HR   OS HR                                        
  ------------------------------------------------------ -------- ------- ------ ------- ------ ------ ------- -------
  Age                                                    1.01     0.98    1.05   0.497   1.04   0.99   1.10    0.130
  T stage                                                1.55     0.89    2.68   0.119   2.12   0.98   4.60    0.057
  N stage                                                3.03     1.04    8.87   0.043   2.55   0.65   10.01   0.181
  ER                                                     0.70     0.19    2.65   0.603   0.61   0.13   2.85    0.532
  HER2                                                   1.12     0.39    3.25   0.836   1.92   0.51   7.20    0.333
  TAM                                                    1.53     0.49    4.77   0.464   0.64   0.13   3.08    0.575
  Other endo[a](#tfn5-ott-9-6407){ref-type="table-fn"}   2.08     0.61    7.09   0.242   1.18   0.27   5.20    0.827
  Chemotherapy                                           0.18     0.03    1.07   0.060   N/A    N/A    N/A     N/A
  GPER1                                                  0.79     0.33    1.93   0.606   1.77   0.53   5.93    0.355

**Note:**

Other endo: other endocrine therapy except for TAM.

**Abbreviations:** DFS, disease-free survival; ER, estrogen receptor; GPER1, G protein-coupled estrogen receptor 1; HR, hazard ratio; N/A, not available; OS, overall survival; TAM, tamoxifen treatment.

###### 

Univariate analysis of DFS and OS in HER2-overexpressed patients

  Factors                                                DFS HR   OS HR                                         
  ------------------------------------------------------ -------- ------- ------- ------- ------ ------ ------- -------
  Age                                                    1.02     0.96    1.09    0.445   1.04   0.98   1.11    0.195
  T stage                                                2.75     2.75    0.73    0.134   1.77   0.41   7.62    0.441
  N stage                                                3.54     1.12    11.22   0.032   3.17   1.00   10.06   0.050
  ER                                                     1.87     0.47    7.47    0.377   0.93   0.23   3.72    0.920
  TAM                                                    1.05     0.22    5.05    0.953   0.81   0.22   2.96    0.754
  Other endo[a](#tfn7-ott-9-6407){ref-type="table-fn"}   2.50     0.63    10.01   0.194   1.24   0.31   4.96    0.761
  Chemotherapy                                           N/A      N/A     N/A     N/A     N/A    N/A    N/A     N/A
  GPER1                                                  4.47     0.926   21.56   0.062   3.56   0.72   17.65   0.12

**Note:**

Other endo: other endocrine therapy except for TAM.

**Abbreviations:** DFS, disease-free survival; ER, estrogen receptor; GPER1, G protein-coupled estrogen receptor 1; HR, hazard ratio; N/A, not available; OS, overall survival; TAM, tamoxifen treatment.

###### 

Multivariate analysis of DFS and OS in HER2-overexpressed patients

  Factors                                                DFS HR   OS HR                                         
  ------------------------------------------------------ -------- ------- ------- ------- ------ ------ ------- -------
  Age                                                    1.02     0.95    1.10    0.602   1.04   0.96   1.13    0.337
  T stage                                                3.72     1.08    12.82   0.037   3.47   1.04   11.50   0.042
  N stage                                                8.15     1.05    63.47   0.045   4.50   0.47   43.01   0.191
  ER                                                     1.15     0.20    6.83    0.876   0.85   0.13   5.53    0.867
  TAM                                                    0.23     0.03    1.72    0.151   0.15   0.02   1.64    0.121
  Other endo[a](#tfn9-ott-9-6407){ref-type="table-fn"}   1.27     0.20    8.01    0.802   0.78   0.12   5.25    0.800
  Chemotherapy                                           N/A      N/A     N/A     N/A     N/A    N/A    N/A     N/A
  GPER1                                                  7.57     1.03    55.58   0.047   6.63   0.93   47.02   0.059

**Note:**

Other endo: other endocrine therapy except for TAM.

**Abbreviations:** DFS, disease-free survival; ER, estrogen receptor; GPER1, G protein-coupled estrogen receptor 1; HR, hazard ratio; N/A, not available; OS, overall survival; TAM, tamoxifen treatment.
